BRANFORD, Conn. / Oct 31, 2024 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that the Company will host an Investor & Analyst event in New York City on November 20th, 2024.
Quantum-Si’s management team will provide updates on the Company’s evolving technology roadmap, emerging applications for protein sequencing and the expanding commercial opportunities that these innovations create.
A live question and answer session will follow the formal presentations.
EVENT DETAILS:
WHEN: Wednesday, November 20, 2024 | 10AM – 12PM EST
WHERE: Westin NY Times Square, 270 West 43rd Street, New York, NY, 10036
REGISTRATION LINK (both in-person & virtual*): QSI Investor Day 2024
*In-person attendance is limited to invited research analysts and institutional investors only. All other guests are invited to view the live or archived webcast virtually on the Investor Relations section of Quantum-Si’s website at https://ir.quantum-si.com/. The archived webcast will be available for at least 90 days following the event.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® instrument enables Next-Generation Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.
| Last Trade: | US$1.15 |
| Daily Change: | -0.01 -0.86 |
| Daily Volume: | 1,613,874 |
| Market Cap: | US$159.160M |
February 18, 2025 February 13, 2025 January 28, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
